RTI Biologics, a provider of orthopedic and other biologic implants, reported quarterly revenues of $45.2 million, a 4 percent increase over the second quarter of 2011. The company's surgical specialties business quarterly revenues reached $8.5 million, an 18 percent increase, while its bone graft substitutes and general orthopedic business quarterly revenues reached $7.0 million, a 12 percent increase. RTI Biologics' sports medicine business line also achieved $13.3 million, a 10 percent increase over the second quarter of 2011.
More Articles on Orthopedic Devices:
Global Spinal Devices and Biologics Market to Grow 6.9% Annually
DePuy Synthes Spine Systems Receive FDA Approval to Treat Scoliosis
Symmetry Medical Announces 2Q Revenue of $102.3M, 8% Increase